Dolutegravir-induced acquired sideroblastic anemia in a HIV positive patient: A challenging hematologic complication.
Kiran DhonjuAshmita GautamAbhinav DahalNiraj Kumar SharmaDivas AdhikariLina DevkotaPrabhat AdhikariSampurna TuladharBishnu Deep PathakSabin BanmalaPublished in: Clinical case reports (2023)
Dolutegravir, the most recent antiretroviral drug with high efficacy, good tolerability, infrequent drug-drug interactions, and a favorable safety profile has not been reported in current literature as a cause of acquired sideroblastic anemia. Here, we present a 35-year-old male patient who was diagnosed with acquired sideroblastic anemia to Dolutegravir therapy.
Keyphrases
- hiv positive
- antiretroviral therapy
- hiv infected patients
- hiv infected
- human immunodeficiency virus
- iron deficiency
- chronic kidney disease
- hiv aids
- men who have sex with men
- south africa
- case report
- drug induced
- systematic review
- clinical trial
- high glucose
- open label
- emergency department
- adverse drug
- randomized controlled trial
- oxidative stress
- double blind